John P. Schmid

Filings by John P. Schmid span 7 companies, the busiest being Anaptysbio, Inc, Xeris Biopharma Holdings, Inc. and Poseida Therapeutics, Inc. Between 5 October 2021 and 10 August 2026, the trades on record add up to 26 filings.

In open-market terms, that means 7 purchases worth €160k on one side and 3 sales worth €1.0M on the other. Taken together, the sales exceed the purchases by €851k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 7 share grants and 5 option exercises. 2026 to date brings 1 purchase and 3 sales.

A typical purchase (the median) is worth €9,284. On 3 out of 7 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 10 August 2026 with an open-market purchase (€83k) in BlossomHill Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.